Amgen: Phase III Trial Shows Denosumab Delayed Skeletal Related Events

Amgen announced results from a Phase III trial evaluating denosumab administered subcutaneously versus Zometa administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors, excluding breast and prostate cancer, or multiple myeloma.
RTTNews